Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GOH
|
|||
| Former ID |
DIB010125
|
|||
| Drug Name |
HepeX-B
|
|||
| Synonyms |
Libivirumab and exbivirumab for injection; XTL-001; Libivirumab + exbivirumab, Cubist/XTL; HBV-Ab(XTL)17 + HBV-Ab(XTL)19
Click to Show/Hide
|
|||
| Indication | Hepatitis virus infection [ICD-11: 1E50-1E51; ICD-9: 573.3] | Phase 2 | [1] | |
| Company |
XTL Biopharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00228592) HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.